RIPK1-IN-41

RIPK1-IN-41 (Compound 5e) potently inhibits purified RIPK1 kinase with an IC₅₀ of 92 nM^[1].
RIPK1-IN-41 directly binds to purified RIPK1 kinase with a K₀ of 106.8 nM^[1].
RIPK1-IN-41 strongly inhibits purified RIPK1, moderately inhibits purified RIPK3, and retains multi-targeted activity against several other kinases including VEGFR2, PDGFRβ, and FLT3^[1].
RIPK1-IN-41 dose-dependently inhibits mTNF-α/Z-VAD-FMK-induced necroptosis in L929 cells with an EC₅₀ of 0.45 μM^[1].
RIPK1-IN-41 (0.05-1 μM) can maintain, in a dose-dependent manner, the mitochondrial integrity and lysosomal integrity of mTNF-α/Z-VAD-FMK-induced necrotic apoptosis in L929 cells, inhibit the formation of RIPK1-RIPK3 necrosomes, upregulate pMLKL activation and lysosomal translocation^[1].
RIPK1-IN-41 (0.5 μM; 3-6 h) time-dependently inhibits the phosphorylation of RIPK1, RIPK3, and MLKL in mTNF-α/Z-VAD-FMK-induced necroptotic L929 cells^[1].
RIPK1-IN-41 (0.05-1 μM,1 h pretreatment; 6 h necroptosis induction) reduced phosphorylation of RIPK1, RIPK3, and MLKL^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.